BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore) 2018;97:e11130. [PMID: 29901640 DOI: 10.1097/MD.0000000000011130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Muralidharan S, Kervarrec T, Weiss GJ, Samimi M. Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma. Oncotarget 2022;13:960-7. [DOI: 10.18632/oncotarget.28260] [Reference Citation Analysis]
2 Han J, Thurnherr T, Chung AYF, Goh BKP, Chow PKH, Chan CY, Cheow PC, Lee SY, Lim TKH, Chong SS, Ooi LLPJ, Lee CG. Clinicopathological-Associated Regulatory Network of Deregulated circRNAs in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2772. [PMID: 34199580 DOI: 10.3390/cancers13112772] [Reference Citation Analysis]
3 Ning X, Li N, Qi Y, Li S, Jia Z, Yang J. Identification of a Hypoxia-Related Gene Model for Predicting the Prognosis and Formulating the Treatment Strategies in Kidney Renal Clear Cell Carcinoma. Front Oncol 2022;11:806264. [DOI: 10.3389/fonc.2021.806264] [Reference Citation Analysis]
4 Ortiz MV, Roberts SS, Glade Bender J, Shukla N, Wexler LH. Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Front Oncol 2019;9:108. [PMID: 30873384 DOI: 10.3389/fonc.2019.00108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
5 Tanaka Y, Tateishi R, Koike K. Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E3070. [PMID: 30297672 DOI: 10.3390/ijms19103070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
6 Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease 2019;30:193-200. [PMID: 31179356 DOI: 10.1007/s13337-019-00517-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Wang JY, Wang XK, Zhu GZ, Zhou X, Yao J, Ma XP, Wang B, Peng T. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer 2021;21:462. [PMID: 33902495 DOI: 10.1186/s12885-021-08104-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Giardino Torchia ML, Letizia M, Gilbreth R, Merlino A, Sult E, Monks N, Chesebrough J, Tammali R, Chu N, Tong J, Meekin J, Schifferli K, Vashisht K, Dacosta K, Clarke L, Gesse C, Yao X, Bridges C, Moody G. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.03.008] [Reference Citation Analysis]
9 Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2020;111:334-42. [PMID: 31774932 DOI: 10.1111/cas.14251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
10 Chen R, Bai Y, Liu T, Zhang G, Han Y, Chen L, Gao H, Wei W, Wang M. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging. Acad Radiol 2021;28:e227-34. [PMID: 32540197 DOI: 10.1016/j.acra.2020.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bakheet AMH, Zhao C, Chen JN, Zhang JY, Huang JT, Du Y, Gong LP, Bi YH, Shao CK. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology. Hepatol Int 2020;14:96-104. [PMID: 31832976 DOI: 10.1007/s12072-019-10006-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer. 2020;11:2008-2021. [PMID: 32127929 DOI: 10.7150/jca.39972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
14 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines (Basel) 2020;8:E41. [PMID: 31991677 DOI: 10.3390/vaccines8010041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
17 Sirisomboonlarp K, Udomsinprasert W, McConachie E, Woraruthai T, Poovorawan Y, Honsawek S. Increased serum glypican-3 is associated with liver stiffness and hepatic dysfunction in children with biliary atresia. Clin Exp Hepatol 2019;5:48-54. [PMID: 30915406 DOI: 10.5114/ceh.2019.83156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Guo XM, Zhu FF, Pan LW, Chen JL, Lai JC, Wu HX, Shu JC. Caprin-1 promotes HepG2 cell proliferation, invasion and migration and is associated with poor prognosis in patients with liver cancer. Oncol Lett 2020;20:1761-71. [PMID: 32724419 DOI: 10.3892/ol.2020.11712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular Carcinoma. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01247-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Glantzounis GK, Karampa A, Peristeri DV, Pappas-Gogos G, Tepelenis K, Tzimas P, Cyrochristos DJ. Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol 2021;34:453-65. [PMID: 34276183 DOI: 10.20524/aog.2021.0632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li N, Spetz MR, Ho M. The Role of Glypicans in Cancer Progression and Therapy. J Histochem Cytochem 2020;68:841-62. [PMID: 32623934 DOI: 10.1369/0022155420933709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
22 Garcia-Jaramillo M, Spooner MH, Löhr CV, Wong CP, Zhang W, Jump DB. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice. PLoS One 2019;14:e0214387. [PMID: 30943218 DOI: 10.1371/journal.pone.0214387] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
23 Lin L, He Y, Ni Z, Zhang M, Liu J, Mao Q, Huang B, Lin J. GPC2 deficiency inhibits cell growth and metastasis in colon adenocarcinoma. Open Medicine 2022;17:304-16. [DOI: 10.1515/med-2022-0421] [Reference Citation Analysis]
24 Natarajan A, Zhang H, Ye W, Huttad L, Tan M, Chua MS, Gambhir SS, So SK. A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. Cancers (Basel) 2021;13:3977. [PMID: 34439132 DOI: 10.3390/cancers13163977] [Reference Citation Analysis]
25 Nomura K, Kitanaka A, Iwama H, Tani J, Nomura T, Nakahara M, Ohura K, Tadokoro T, Fujita K, Mimura S, Yoneyama H, Kobara H, Morishita A, Okano K, Suzuki Y, Tsutsi K, Himoto T, Masaki T. Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. Oncol Lett 2021;21:229. [PMID: 33613718 DOI: 10.3892/ol.2021.12490] [Reference Citation Analysis]
26 Rahbari M, Pecqueux M, Aust D, Stephan H, Tiebel O, Chatzigeorgiou A, Tonn T, Baenke F, Rao V, Ziegler N, Greif H, Lin K, Weitz J, Rahbari NN, Kahlert C. Expression of Glypican 3 is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes. J Clin Med 2019;8:E696. [PMID: 31100935 DOI: 10.3390/jcm8050696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Xu Y, Yuan X, Zhang X, Hu W, Wang Z, Yao L, Zong L. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e26506. [PMID: 34160470 DOI: 10.1097/MD.0000000000026506] [Reference Citation Analysis]
28 Yorita K, Ohno A, Nishida T, Kondo K, Ohtomo T, Kataoka H. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Res Notes 2019;12:741. [PMID: 31706332 DOI: 10.1186/s13104-019-4778-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Zhao X, Zou J, Wang Z, Li G, Lei Y. Identifying Novel Cell Glycolysis-Related Gene Signature Predictive of Overall Survival in Gastric Cancer. Biomed Res Int 2021;2021:9656947. [PMID: 33791386 DOI: 10.1155/2021/9656947] [Reference Citation Analysis]
30 Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, Cen B, Wei X, Wei Q, Xie H, Xu X. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chin J Cancer Res 2021;33:470-9. [PMID: 34584372 DOI: 10.21147/j.issn.1000-9604.2021.04.04] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chong H, Gong Y, Zhang Y, Dai Y, Sheng R, Zeng M. Radiomics on Gadoxetate Disodium-enhanced MRI: Non-invasively Identifying Glypican 3-Positive Hepatocellular Carcinoma and Postoperative Recurrence. Acad Radiol 2022:S1076-6332(22)00254-9. [PMID: 35562264 DOI: 10.1016/j.acra.2022.04.006] [Reference Citation Analysis]
32 Shibui Y, Miyoshi K, Kohashi K, Kinoshita Y, Kuda M, Yamamoto H, Taguchi T, Oda Y. Glypican-3 expression in malignant small round cell tumors. Oncol Lett 2019;17:3523-8. [PMID: 30867793 DOI: 10.3892/ol.2019.9976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]